Cardiac safety of modified vaccinia ankara for vaccination against smallpox in a young, healthy study population

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Zitzmann Roth, Eva Maria ^a   Von Sonnenburg, Frank ^b   De La Motte, Stephan ^c   Arndtz Wiedemann, Nathaly ^d   Von Krempelhuber, Alfred ^d,e   Uebler, Nadine ^d,f   Vollmar, Jens ^d,e   Virgin, Garth ^d,g   Chaplin, Paul ^d  

^a Praxis Zitzmann Roth   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Harrison Clinical Research GmbH   (Germany)

^d Bavarian Nordic GmbH   (Germany)

^e GLAXOSMITHKLINE   (Germany)

^f Vifor Pharma Deutschland GmbH Baierbrunner Strasse 29 ^*  (Germany)

^g Vifor (International) Inc   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA VIRUS VACCINE; PLACEBO; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART SUPRAVENTRICULAR ARRHYTHMIA; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INJECTION SITE BLEEDING; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LYMPHADENOPATHY; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PERICARDIAL EFFUSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SAFETY; SINUS TACHYCARDIA; SMALLPOX; SORE THROAT; TACHYCARDIA; TREATMENT OUTCOME; VACCINATION; DRUG EFFECTS;

POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

ADULT; FEMALE; HEALTHY VOLUNTEERS; HEART; HUMANS; MALE; SMALLPOX VACCINE;

EID: 84928143355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122653     Document Type: Article

References (36)

1. Suter M, Meisinger-Henschel C, Tzatzaris M, Hulsemann V, Lukassen S, Wulff NH, et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine.
2. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281: 1201-1208. PMID: 4186802
3. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122: 303-309. PMID: 4396189
4. Mayr A, Munz E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralbl Bakteriol [Orig] 1964; 195: 24-35. PMID: 5890664
5. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974; 99: 2386-2392. PMID: 4426258
6. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. Infection 1975; 3: 6-14.
7. Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell CL, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004; 44: 201-205. PMID: 15234435
8. Morgan J, Roper MH, Sperling L, Schieber RA, Heffelfinger JD, Casey CG, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis 2008; 46 Suppl 3: S242-S250. doi: 10.1086/524747 PMID: 18284365
9. Mora LF, Khan AH, Sperling LS. Cardiac Complications after Smallpox Vaccination. South Med J 2009; 102: 615-619 doi: 10.1097/SMJ.0b013e31819fe55b PMID: 19434043
10. Sharma U, Tak T. A report of 2 cases of myopericarditis after Vaccinia virus (smallpox) immunization. WMJ 2011; 110: 291-294. PMID: 22324207
11. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 2003; 289: 3278-3282. PMID: 12824209
12. Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol 2005; 95: 1252-1255. PMID: 15878006
13. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43: 1503-1510. PMID: 15120802
14. MMWR. Update: adverse events following civilian smallpox vaccination - United States, 16.05.2003. MMWR Morb Mortal Wkly Rep 2003; 52: 444-446. PMID: 12807087
15. Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, Engler RJ, et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004; 160: 642-651. PMID: 15383408
16. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289: 3283-3289. PMID: 12824210
17. Sniadack MM, Neff LJ, Swerdlow DL, Schieber RA, McCauley MM, Mootrey GT. Follow-up of cardiovascular adverse events after smallpox vaccination among civilians in the United States, 2003. Clin Infect Dis 2008; 46 Suppl 3: S251-S257. doi: 10.1086/524741 PMID: 18284366
18. Acambis (2007) ACAM2000 Smallpox Vaccines: Vaccines and Related Biological Products Advisory Committee (VRBPAC). Acambis Briefing Document, April 2007.
19. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 2005;70: 61134-61135.
20. ACAM2000 Prescribing Information. Package Insert. 2011.
21. Kobza R, Cuculi F, Abacherli R, Toggweiler S, Suter Y, Frey F, et al. Twelve-lead electrocardiography in the young: physiologic and pathologic abnormalities. Heart Rhythm 2012; 9: 2018-2022. doi: 10.1016/j.hrthm.2012.08.034 PMID: 23102624
22. Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kothari S, Narula D, et al. Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies. Indian J Med Res 2012; 135: 322-330. PMID: 22561618
23. Hiss RG, Lamb LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25: 947-961. PMID: 13907778
24. Sano J, Chaitman BR, Swindle J, Frey SE. Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination. Am J Med 2009; 122: 79-84. doi: 10.1016/j.amjmed.2008.07.025 PMID: 19114175
25. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24: 2065-2070. PMID: 16337719
26. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007; 25: 8562-8573. PMID: 18036708
27. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28: 1209-1216. doi: 10.1016/j.vaccine.2009.11.030 PMID: 19944151
28. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009; 8: 13-24. doi: 10.1586/14760584.8.1.13 PMID: 19093767
29. Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von KA, Virgin G, et al. Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects. J Infect Dis 2013; 207: 749-758. doi: 10.1093/infdis/jis753 PMID: 23225902
30. Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, et al. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review. PLoS ONE 2013; 8: e54407. doi: 10.1371/journal.pone.0054407 PMID: 23349878
31. Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, et al. Safety and immunogenicity of IMVAMUNE((R)) smallpox vaccine using different strategies for a post event scenario. Vaccine 2013; 31: 3025-3033. doi: 10.1016/j.vaccine.2013.04.050 PMID: 23664987
32. Neumayr G, Gaenzer H, Pfister R, Sturm W, Schwarzacher SP, Eibl G, et al. Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise. Am J Cardiol 2001; 87: 369-71, A10. PMID: 11165984
33. Eijsvogels T, George K, Shave R, Gaze D, Levine BD, Hopman MT, et al. Effect of prolonged walking on cardiac troponin levels. Am J Cardiol 2010; 105: 267-272. doi: 10.1016/j.amjcard.2009.08.679 PMID: 20102930
34. Nosanchuk JS, Combs B, Abbott G. False increases of troponin I attributable to incomplete separation of serum. Clin Chem 1999; 45: 714. PMID: 10223785
35. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104-1121. PMID: 10388496
36. Neff J, Modlin J, Birkhead GS, Poland G, Robertson RM, Sepkowitz K, et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008; 46 Suppl 3: S258-S270. doi: 10.1086/524749 PMID: 18284367